Diversified financial services company.
Biotech issues impacting small cap companies. Small cap liquidity issues relating to tick-size legislation and tick-size SEC pilot program.  Venture Exchange issues relating to creating liquidity and capital access for smaller companies.
MiFIDII  relating to European regulations limiting payments for research. Biotech issues impacting small cap firms.
HCR - Health Issues FIN - Financial Institutions/Investments/Securities MED - Medical/Disease Research/Clinical Labs
2 - HOUSE OF REPRESENTATIVES 88 - Securities & Exchange Commission (SEC) 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 88 - Securities & Exchange Commission (SEC) 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 88 - Securities & Exchange Commission (SEC) 1 - SENATE
DC STRATEGIES GROUP, LLC
1775 I Street, NW, Suite 1150, Washington, DC, 20006, US
ROY DELOACH MICHAEL D CHAPMAN ROY DELOACH MICHAEL D CHAPMAN ROY DELOACH MICHAEL D CHAPMAN